Coherus/BAX announce positive PK study for Enbrel FoB, CHS-0214: http://finance.yahoo.com/news/coherus-announces-chs-0214-proposed-115900393.html CHS-0214 is being developed for the EU, Canada, Brazil, and other emerging markets. (In the US, AMGN’s patent protection precludes an FoB until 2028, until the patent is successfully challenged: #msg-69263618.)